DSGN Stock Analysis: Buy, Sell, or Hold?
DSGN - Design Therapeutics, Inc. Common Stock
$14.35
-0.84 (-5.56%)
▼
5d:
-3.4%
30d:
+34.57%
90d:
+17.97%
BUY
HIGH Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 06, 2026
23d
Get Alerted When DSGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DSGN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: DSGN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: DSGN is currently trading at $14.35, which is considered slightly high relative to its 30-day fair value range of $11.14 to $14.83.
Technical Outlook: Technically, DSGN is in a strong uptrend. Immediate support is located at $13.03, while resistance sits at $15.86. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: DSGN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (2th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.00 (+38.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DSGN is in a strong uptrend. Immediate support is located at $13.03, while resistance sits at $15.86. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: DSGN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (2th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.00 (+38.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$11.14 -
$14.83
Company Quality Score
64/100
(BUY)
Options IV Signal
2th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
79.2%
All Signals
- BULLISH: Options cheap (IV 2th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 38.2% below Wall St target ($21.00)
Trading Range Analysis
30-Day Trading Range
$11.14 -
$14.83
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$2.82
(19.7%)
Support & Resistance Levels
Support Level
$13.03
Resistance Level
$15.86
Current Trend
Strong Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.29
Wall Street Target
$21.00
(+38.2%)
Share & Embed Analysis
Last updated: July 13, 2026 11:11 AM ET
Data refreshes hourly during market hours. Next update: 12:11 PM
Data refreshes hourly during market hours. Next update: 12:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DSGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 55 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
